• Safe for all skin types: The Dermapen 4® is a non-thermal, non-ablative device, making it a safe choice for darker skin types where lasers might carry a higher risk of post-inflammatory hyperpigmentation (PIH).

• Uniform drug delivery: Microneedling creates 1,920 controlled micro-channels per second, enabling the even, deep infusion of active lightning agents directly to the source of pigmentation.

• Precision depth control: Practitioners can customise needle depth to target epidermal melasma with erythema as an endpoint, or deeper dermal melasma, which may require a pinpoint bleeding endpoint.

• Regenerative healing: The process triggers a controlled wound-healing response that normalises cellular signalling between keratinocytes and melanocytes.

• Minimal downtime: Controlled micro-channels close quickly, typically resulting in a fast healing process of one to three days with very manageable recovery for the patient.

Dr Jaishree Sharad detailed the complex pathway of melanogenesis, emphasising why a precise, "bottom-up" and "top-down" approach is essential for success. She explained that melasma is not just about the melanocyte but involves a cascade of hormonal and environmental triggers:

• Enzymatic control: Tyrosinase is the rate-limiting enzyme in pigment production; precision treatment involves delivering inhibitors like kojic acid and Vitamin C directly to where this enzyme is active.

• Cellular normalisation: Microneedling helps rebalance melanogenesis and strengthens cell membranes to resist "melanin leaking".

• Targeting melanophages: For deeper dermal melasma, precision enables practitioners to reach pigment-containing macrophages in the superficial papillary dermis.

A key highlight of the webinar was the integration of specialised solutions to amplify results. Dr Sharad presented how combining mechanical stimulation with chemical signalling redefines melasma treatment:

• Synergistic infusions: Using Dp Dermaceuticals MG-BL™ during the procedure provides an effective cocktail of tyrosinase inhibitors, including tranexamic acid, kojic acid, and licorice.

• The power of tranexemic acid: This key ingredient inhibits UV-induced plasmin activity, effectively diminishing the skin's ability to produce pigment at the source.

• Advanced peel technology: The application of Dp Dermaceuticals ÜBER PRO™—a specialised anabolic peel—following microneedling enhances resurfacing and pigment removal without the downtime of traditional peels.

The success of the "Melasma Mastery" protocol relies on a comprehensive approach that extends from the clinic to the patient’s home.

• Broad-spectrum protection: Daily use of a tinted sunscreen like Dp Dermaceuticals COVER RECOVER™ is non-negotiable, as it blocks harmful blue light and UV rays that trigger relapse.

• Internal support: Dr Sharad advocates for oral antioxidants and systemic agents to reduce the oxidative triggers of melanogenesis from within.

• Strategic maintenance: Long-term adherence to topical therapies and strict photo protection is essential to prevent rebound hyperpigmentation and ensure sustained results.